bioMérieux, a world leader in the field of in vitro diagnostics, has announced the launch of BIOFIRE® MYCOPLASMA, an innovative test for mycoplasma detection in pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.),...
bioMérieux, a world leader in the field of in vitro diagnostics, today announced that the BIOFIRE® Respiratory Panel 2.1 plus (RP2.1plus) is CE marked. The BIOFIRE® Respiratory Panel 2.1 plus (RP2.1plus) tests for 23...
In light of the withdrawal of its annual objectives, bioMérieux, a world leader in the field of in vitro diagnostics, today announced preliminary quarterly information about its business activity ending June 30, 2020.
Marcy l’Étoile (France) - June 29, 2020 – bioMérieux, a global leader in the field of in vitro diagnostics, announces that it has successfully issued today a €200 million Euro PP new debt with a top-tier European institutional...
bioMérieux, a world leader in the field of in vitro diagnostics, today announced the CE marking of VIDAS® anti-SARS-CoV-2 serology tests to detect...
The Board of Directors of bioMérieux met today and decided to hold the annual General Shareholders’ Meeting behind closed doors at the bioMérieux registered office on June 30, 2020. During this meeting, it will recommend reducing the 2019 dividend in order to support initiatives in the...
bioMérieux, a world leader in the field of in vitro diagnostics, today announced performance validation and the upcoming launch of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to the SARS-CoV...
bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in syndromic infectious disease testing, has received Emergency Use Authorization by the U.S. Food and Drug Administration...
